Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens

YILDIZ R., Buyukberber S., ÜNER A., Yamac D., Coskun U., Kaya A. O., ...Daha Fazla

CANCER INVESTIGATION, cilt.28, sa.1, ss.33-37, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2010
  • Doi Numarası: 10.3109/07357900802562996
  • Dergi Adı: CANCER INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.33-37
  • Anahtar Kelimeler: Bevacizumab, Irinotecan, Metastatic colorectal cancer, Oxaliplatin-resistant, MULTICENTER PHASE-II, BOLUS FLUOROURACIL, 1ST-LINE TREATMENT, CONTROLLED-TRIAL, LEUCOVORIN, 2ND-LINE, 5-FLUOROURACIL, CHEMOTHERAPY, COMBINATION, INFUSION
  • Gazi Üniversitesi Adresli: Evet

Özet

Background. Treatment of patients with metastatic colorectal cancer (MCRC) previously exposed to oxaliplatin-based regimen is challenging. Efficacy and toxicity of bevacizumab plus irinotecan-based regimens were assessed in the second-line treatment of MCRC patients. Patients and Methods: Forty patients with a median age of 53 years (range, 31-75) were retrospectively evaluated. Patients progressing or relapsing after treatment with oxaliplatin-based regimens were given bevacizumab 5 mg/kg every 2 weeks in combination with irinotecan-based regimens. All patients had previously received oxaliplatin either in the adjuvant setting (n = 8) or for metastatic disease (n = 32). Results: Three patients achieved a complete response (7.5%),5 partial responses (12.5%) and 14 (35%) stable disease resulting in an overall response rate of 20%. Median progression-free survival was 6 months (95% CI, 4.0-8.0) with a median overall survival of 14 months (95% CI, 10.2-17.8). One-year survival rate was 55.9%. Grade 3-4 toxicities were as follows: neutropenia (n = 15, 37.5%), febrile neutropenia (n = 2, 5%), diarrhea (n = 11, 27.5%), nausea and vomiting (n = 3, 7.5%), gastrointestinal perforation (n = 2, 5%), and thromboembolism (n = 2, 5%). Conclusion: Bevacizumab plus irinotecan-based combination chemotherapy is an active and safe treatment option in patients failing oxaliplatin-based therapy.